The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fuzuloparib combined with abiraterone acetate and prednisone (AA-P) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Interim results from the FUZUPRO trial.
 
Dingwei Ye
No Relationships to Disclose
 
Hua Xu
No Relationships to Disclose
 
Mariusz Kwiatkowski
No Relationships to Disclose
 
Chaochao Liang
No Relationships to Disclose
 
Jose Angel Arranz Arija
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Merck; MSD Oncology; Novartis; Pfizer; Recordati
Speakers' Bureau - Merck; Pfizer; Pfizer
Research Funding - Bristol-Myers Squibb (Inst)
 
Shusuan Jiang
No Relationships to Disclose
 
Young Seuk Choi
No Relationships to Disclose
 
Tie Chong
No Relationships to Disclose
 
Chaohong He
No Relationships to Disclose
 
Jiwen Cheng
No Relationships to Disclose
 
HongQian Guo
No Relationships to Disclose
 
Thean Tan
No Relationships to Disclose
 
Jae Young Joung
No Relationships to Disclose
 
Sung Kyu Hong
No Relationships to Disclose
 
Ting Sung
No Relationships to Disclose
 
Begoña Valderrama
Honoraria - AAA HealthCare; Almirall; Astellas Pharma; AstraZeneca Spain; Bayer; Bristol-Myers Squibb/Medarex; Janssen Oncology; Merck; MSD Oncology; Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Janssen Oncology; Merck; MSD Oncology; Pfizer; Recordati
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Merck; Merck; MSD Oncology; Pfizer; Roche
 
Tomáš Büchler
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); MSD (Inst); Novartis (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Ipsen
 
Yiwen Wu
Employment - Jiangsu Hengrui Pharmaceuticals
 
Fan Liang
Employment - Jiangsu Hengrui Pharmaceuticals
 
Wenliang Wang
Employment - Jiangsu Hengrui Pharmaceuticals